Why are long-acting beta-adrenoceptor agonists long-acting?

Area of Science:

• Pharmacology
• Respiratory Medicine
• Molecular Biology

Background:

• Long-acting beta 2-adrenoceptor agonists (LABAs) like formoterol and salmeterol provide prolonged bronchodilation, exceeding that of short-acting agents.
• Their sustained effect and ability to reassert relaxation in vitro have led to debate regarding their mechanism of action.

Purpose of the Study:

• To investigate the underlying mechanisms responsible for the extended duration of action of formoterol and salmeterol.
• To challenge the existing exosite/exoceptor model and propose an alternative hypothesis for LABA action.

Main Methods:

• Comparative pharmacology of formoterol, salmeterol, and short-acting beta 2-adrenoceptor agonists.
• Molecular modeling of drugs, beta 2-adrenoceptor, and ligand binding.
• In vitro studies on human airway smooth muscle, including drug-induced relaxation and washing experiments.

Main Results:

• Evidence suggests the exosite/exoceptor model is unlikely to explain salmeterol's behavior.
• A unifying hypothesis proposes that physicochemical interactions with membrane lipid bilayers (plasmalemma diffusion microkinetic model) primarily determine the duration of action for both formoterol and salmeterol.
• This model better explains the pharmacological profiles, including onset, duration, reassertion, and interactions with antagonists.

Conclusions:

• The duration of action of formoterol and salmeterol is mainly governed by their interaction with cell membrane lipids, not distinct exoceptor sites.
• The plasmalemma diffusion microkinetic model offers a clearer understanding of LABA pharmacology.
• This model may explain the absence of a true relaxation-concentration response for salmeterol in human airway smooth muscle in vitro.